6th Annual

Kinase Inhibitor Chemistry

Shaping Current and Future Development of Kinase Inhibitors

April 22-23, 2015 


Up-to-date discussion on late breaking strategies for novel kinase inhibitor design.

Ann A., Senior Scientist, Pfizer

The human kinome is a large and highly druggable class of targets spanning numerous disease indications, and has lead to a significant portion of all drug development efforts geared toward the discovery and optimization of chemical matter modulating kinase activity. Yet, despite the hundreds of kinase inhibitors currently in discovery, pre-clinical, and clinical phases, a relatively small subset of the kinome has been thoroughly explored with selective small molecule inhibitors. Thus, in this highly competitive space, overcoming current challenges of identifying novel kinase targets, obtaining target selectivity and specificity, and developing inhibitors that bind outside the ATP site, provide clear opportunities for continued development.

Cambridge Healthtech Institute’s 6th Annual Kinase Inhibitor Chemistry will once again bring together academic and industry leaders to network, collaborate and discuss practical solutions to these challenges, while exploring the ever expanding arena of kinase drug discovery. Join fellow drug discovery scientists for this day-and-a-half meeting that is in the second half of CHI's larger Drug Discovery Chemistry event.

Topics may include, but are not limited to: 

  • High-Throughput Screening
  • Virtual Screening
  • Biochemical & Cell-Based Assays
  • Fragment and Structure-Based Design
  • Chemical Biology
  • In Silico Modeling
  • Macrocycle Inhibitors
  • Covalent Inhibitors
  • Allosteric Modulators
  • Phenotypic Screening
  • Lead Optimization

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is September 22, 2014 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.  Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Kip Harry
Conference Producer
Cambridge Healthtech Institute
Phone: (+1) 781-972-5454
Email: kharry@healthtech.com 

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com